The DAgre Net III DAPA-CKD test reached all major endpoints and secondary endpoints.

July 28, 2020 -- High levels of DAPA-CKD study in Daglinet (Andadon ®) III showed that in patients with chronic kidney disease, the main compound endpoint of the risk of deterioration of kidney function or death (defined as the estimated rate of renal glomerular filtration eGFR continued to decline by 50%, the progress of which was a compound endpoint of end-stage kidney disease or cardiovascular/cardiovascular/patient death) with statistical lysage and clinical lying.
study also reached all secondary endpoints in patients with chronic kidney disease with or with or with type 2 diabetes, making Dagre net the first drug to significantly reduce the total cause of death in such patients.
chronic kidney disease is a serious progressive disease defined as a decline in renal function, affecting nearly 700 million people worldwide 1,2, which includes many undiagnosed patients 3,4.
currently limited treatment for such patients5.
chronic kidney disease is associated with significant incidence of patients, as well as increased risk of cardiovascular events, such as heart failure and premature death7. Professor David Wheeler, co-chair of the executive committee of the
Study, Professor David Wheeler of University College London, and Professor Hiddo L. Heerspink of the University medical centre of Groningen, said: "The DAPA-CKD study shows the potential of Dagre net, which may be the long-awaited new option for treatment in patients with chronic kidney disease.
these data will have a revolutionary impact on this type of patient. "The DAPA-CKD trial is the first to demonstrate that the DAGrynet has the associated efficacy of developing, including improved survival rates, in patients with chronic kidney disease with or withors eside type 2 diabetes," said Mene Pangalos, Executive Vice President of Research and Development at
.
we look forward to sharing these exciting results with scientific organizations and health authorities around the world.
"dagre net safety and tolerance are consistent with the safety of mature drugs that have been used clinically.
the full results of the DAPA-CKD trial will be presented at a recent medical conference.
March 2020, AstraZeneca announced that, based on the recommendations of the Independent Data Monitoring Board (DMC), the Dagre Net Prevention of Renal Adverse Outcomes (DAPA-CKD) III trial has been terminated prematurely, based on the clear and overwhelming efficacy of Dagre Net for patients with chronic kidney disease.
References1.Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney International Supplement 2013; (3): 1-150.2.GBD 2017 Global, regional, and national, and national, and years lived with disability for 354 diseases and sons for 195 countries and ies, 1990-2017: a analysis for the global Burden of The Study 2017 392:1789-858.3. National Kidney Foundation. Disease Kidney: The Basics .cited 07.08.20. Available from: URL: 4.Hirst JA et al. Prevalence of chronic kidney disease in the community using data from OxRen: A population UK-based cohort study. Br J Gen Pract 2020; 70 (693): e285-e293.5. Ward F et al. Drug therapies to delay the progression of chronic kidney disease. Clin Med (Lond) 2015; 15 (6) 550-76.Bikbov, Boris, et al. "Global, Regional, and National Burden of Chronic sleuthes of Kidney Disease, 1990-2017: a Media R. For the Global Burden Of The Disease 2017." The Lancet, vol. 395, no. 10225, 13 Feb. 2020, pp. 709-733., doi: 10.1016/s0140-6736 (20) 30045-3.7. Segall L et al Heart al s. Biomed Res Int 2014; 2014: 937398.8. National Kidney Foundation. Disease Kidney: Causes, 2017; (Cited 2020 Jun 25. Available from URL: 9.Centers for Disease Control and Prevention. Chronic Disease Kidney in the United States, 2019 .10.05.20. Available from URL: 10.Briasoulis A, Bakris GL. Chronic Kidney Disease as a coronary disease Disease Risk Associates. Cur Cardiol Rep 2013; 15(3): 340.Source:MedSci Original !-- Content Presentation Ends -- !-- Determine Sending Out